Akari Therapeutics, Plc

NasdaqCM AKTX

Akari Therapeutics, Plc Operating Income for the year ending December 31, 2023: USD -16.81 M

Akari Therapeutics, Plc Operating Income is USD -16.81 M for the year ending December 31, 2023, a 27.21% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Akari Therapeutics, Plc Operating Income for the year ending December 31, 2022 was USD -23.09 M, a -34.12% change year over year.
Akari Therapeutics, Plc Operating Income for the year ending December 31, 2021 was USD -17.21 M, a 4.26% change year over year.
Akari Therapeutics, Plc Operating Income for the year ending December 31, 2020 was USD -17.98 M, a 27.70% change year over year.
Akari Therapeutics, Plc Operating Income for the year ending December 31, 2019 was USD -24.87 M, a -24.40% change year over year.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqCM: AKTX

Akari Therapeutics, Plc

CEO	Dr. Samir Rashmikant Patel M.D.
IPO Date	Jan. 6, 2014
Location	United Kingdom
Headquarters	75/76 Wimpole Street
Employees	6
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Key trends

Past 5 years